Want to see GB:CREO full AI Analyst Report?
CREO Stock Chart & Stats
13.62 p
0.13 p(0.92%)
At close: 4:00 PM EDT
13.62 p
0.13 p(0.92%)
Day’s Range― - ―
52-Week Range9.52 p - 18.50 p
Previous CloseN/A
Volume174.00K
Average Volume (3M)975.48K
Market Cap
£58.95M
Enterprise Value32.53 p
Total Cash (Recent Filing)£12.40M
Total Debt (Recent Filing)£4.10M
Price to Earnings (P/E)10.4
Beta1.05
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding449,139,980
10 Day Avg. Volume668,834
30 Day Avg. Volume975,484
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.82
Price to Sales (P/S)6.81
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£9.10M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow leverage and a sizable equity base provide financial flexibility for continued commercialisation and product investment. This reduces near-term balance-sheet pressure, although ongoing losses could gradually weaken that cushion.
Platform And Consumables ModelThe combination of capital equipment and procedure-linked consumables can support repeat purchasing after hospital adoption. A growing installed base could therefore improve revenue visibility and deepen customer relationships over time.
2025 Revenue ImprovementThe 2025 revenue improvement indicates that commercial traction may be strengthening after a period of uneven performance. Sustained growth would help spread fixed costs across a larger base and improve the path toward operating leverage.
Bears Say
Persistent Operating LossesLarge recurring operating losses show that the cost base remains well ahead of current revenue scale. Unless commercial growth accelerates or spending becomes more efficient, profitability could remain structurally distant.
Sustained Cash BurnPersistent negative operating and free cash flow means the business is not yet self-funding. Continued investment and commercial expansion may require existing cash or future financing, increasing execution and dilution risk.
Volatile Core PerformanceUneven revenue trends make forecasting and capacity planning more difficult. The divergence between positive net income and heavy operating losses also suggests bottom-line results may not yet reflect durable improvement in the core business.
Creo Medical News
CREO FAQ
What was Creo Medical Group PLC’s price range in the past 12 months?
Creo Medical Group PLC lowest share price was 9.52 p and its highest was 18.50 p in the past 12 months.
What is Creo Medical Group PLC’s market cap?
Creo Medical Group PLC’s market cap is £58.95M.
When is Creo Medical Group PLC’s upcoming earnings report date?
Creo Medical Group PLC’s upcoming earnings report date is Sep 30, 2026 which is in 30 days.
How were Creo Medical Group PLC’s earnings last quarter?
Creo Medical Group PLC released its earnings results on May 22, 2026. The company reported -0.028 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Creo Medical Group PLC overvalued?
According to Wall Street analysts Creo Medical Group PLC’s price is currently Overvalued.
Does Creo Medical Group PLC pay dividends?
Creo Medical Group PLC does not currently pay dividends.
What is Creo Medical Group PLC’s EPS estimate?
Creo Medical Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Creo Medical Group PLC have?
Creo Medical Group PLC has 449,139,980 shares outstanding.
What happened to Creo Medical Group PLC’s price movement after its last earnings report?
Creo Medical Group PLC reported an EPS of -0.028 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 27.473%.
Which hedge fund is a major shareholder of Creo Medical Group PLC?
Currently, no hedge funds are holding shares in GB:CREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Creo Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
Creo Medical Group PLC
Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquartered in Chepstow, the company's core offering is Croma, an advanced energy platform. This platform is engineered to power a diverse collection of multi-modal instruments, thereby enhancing therapeutic interventions for both medical professionals and patients. Its extensive product portfolio includes specialized tools such as Speedboat Inject, an adaptable energy instrument designed for flexible endoscopic procedures; Speedboat Slim, a flexible bipolar radiofrequency (RF) and microwave device for precise tissue cutting and coagulation; MicroBlate Fine, a microwave needle for ablation; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device engineered to control upper and lower gastrointestinal bleeds; and SpydrBlade Flex, a flexible scissor-like instrument that integrates bipolar RF and microwave technology to grasp, cut, and coagulate highly vascularized tissues.